Kalaris Therapeutics, Inc. Net Assets
Kalaris Therapeutics, Inc. net assets. Based on the latest financial reports, Kalaris Therapeutics, Inc. (KLRS) has net assets worth $68.56 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($109.81 Million) and total liabilities ($41.25 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Kalaris Therapeutics, Inc. equity growth rate to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $68.56 Million |
| % of Total Assets | 62.44% |
| Annual Growth Rate | 20.32% |
| 5-Year Change | -65.01% |
| 10-Year Change | N/A |
| Growth Volatility | 210.38 |
Net Assets of Kalaris Therapeutics, Inc. (2018–2025)
Net assets of Kalaris Therapeutics, Inc. from 2018 to 2025. This chart illustrates how Kalaris Therapeutics, Inc.'s net assets have evolved over time, based on quarterly financial data. See Kalaris Therapeutics, Inc. (KLRS) balance sheet quality index to measure how much of total assets are equity-financed.
Annual Net Assets for Kalaris Therapeutics, Inc. (2018–2025)
The table below shows the annual net assets of Kalaris Therapeutics, Inc. from 2018 to 2025. For live market cap and overall valuation, see market cap of Kalaris Therapeutics, Inc..
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $78.81 Million | -30.44% |
| 2024-12-31 | $113.31 Million | +351.70% |
| 2023-12-31 | $-45.02 Million | -48.71% |
| 2022-12-31 | $-30.27 Million | -113.44% |
| 2021-12-31 | $225.27 Million | -36.20% |
| 2020-12-31 | $353.06 Million | +190.29% |
| 2019-12-31 | $121.62 Million | +463.54% |
| 2018-12-31 | $21.58 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Kalaris Therapeutics, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 12851900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Kalaris Therapeutics, Inc. Net Assets Breakdown (December 2025)
Kalaris Therapeutics, Inc. net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.00K | 0.00% |
| Other Comprehensive Income | $6.00K | 0.01% |
| Other Components | $238.81 Million | 303.00% |
| Total Equity | $78.81 Million | 100.00% |
Kalaris Therapeutics, Inc. Competitors by Market Cap
The table below lists competitors of Kalaris Therapeutics, Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Tritax Big Box REIT plc
LSE:BBOX
|
$48.78 Million |
|
SIL Investments Limited
NSE:SILINV
|
$48.79 Million |
|
Mereo BioPharma Group PLC ADR
NASDAQ:MREO
|
$48.79 Million |
|
Analabs Resources Bhd
KLSE:7083
|
$48.79 Million |
|
Maison Antoine Baud Société Anonyme
PA:MLMAB
|
$48.77 Million |
|
Promateris SA
RO:PPL
|
$48.76 Million |
|
Connect Biopharma Holdings Ltd
NASDAQ:CNTB
|
$48.75 Million |
|
Sinil Pharmaceutical Co. Ltd
KQ:012790
|
$48.73 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Kalaris Therapeutics, Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 113,307,000 to 78,814,000, a change of -34,493,000 (-30.4%).
- Net loss of 43,438,000 reduced equity.
- New share issuances of 42,000,000 increased equity.
- Other comprehensive income increased equity by 141,000.
- Other factors decreased equity by 33,196,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-43.44 Million | -55.11% |
| Share Issuances | $42.00 Million | +53.29% |
| Other Comprehensive Income | $141.00K | +0.18% |
| Other Changes | $-33.20 Million | -42.12% |
| Total Change | $- | -30.44% |
Book Value vs Market Value Analysis
This analysis compares Kalaris Therapeutics, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.40x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.27x to 0.40x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $7.62 | $2.05 | x |
| 2019-12-31 | $42.97 | $2.05 | x |
| 2020-12-31 | $301.91 | $2.05 | x |
| 2021-12-31 | $82.53 | $2.05 | x |
| 2022-12-31 | $-9.08 | $2.05 | x |
| 2023-12-31 | $-9.95 | $2.05 | x |
| 2024-12-31 | $22.62 | $2.05 | x |
| 2025-12-31 | $5.16 | $2.05 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Kalaris Therapeutics, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -55.11%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.54x
- Recent ROE (-55.11%) is below the historical average (-29.24%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -11.26% | -214.10% | 0.04x | 1.17x | $-4.59 Million |
| 2019 | -19.60% | -14447.88% | 0.00x | 1.15x | $-36.00 Million |
| 2020 | -19.77% | 0.00% | 0.00x | 1.05x | $-105.09 Million |
| 2021 | -76.34% | 0.00% | 0.00x | 1.27x | $-194.49 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-12.46 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-10.20 Million |
| 2024 | -51.87% | 0.00% | 0.00x | 1.05x | $-70.10 Million |
| 2025 | -55.11% | 0.00% | 0.00x | 1.54x | $-51.32 Million |
Industry Comparison
This section compares Kalaris Therapeutics, Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $154,916,114
- Average return on equity (ROE) among peers: -15.75%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Kalaris Therapeutics, Inc. (KLRS) | $68.56 Million | -11.26% | 0.60x | $48.77 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $26.78 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $-5.83 Million | 0.00% | 0.00x | $243.03 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $16.93 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $40.92 Million | 73.18% | 0.29x | $768.65 Million |
| ABVC Biopharma Inc (ABVC) | $29.08K | -111.02% | 1.35x | $26.26 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $7.74 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $182.13 Million | -20.84% | 0.04x | $3.54 Billion |
About Kalaris Therapeutics, Inc.
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudativ… Read more